Glass House Brands (GLAS) Gross Profit (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Gross Profit of $10.0 million for Q1 2026, down 24.16% quarter-over-quarter from $13.2 million in Q4 2025.

Glass House Brands (GLAS) Gross Profit (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Gross Profit for 7 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Gross Profit changed N/A year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $66.9 million (changed N/A YoY), while the FY2025 annual figure was $77.0 million, down 20.98% from the prior year.
Gross Profit slipped to $10.0 million in Q1 2026 per GLAS's latest filing, from $13.2 million in the prior quarter.
Across five years, Gross Profit topped out at $31.9 million in Q2 2025 and bottomed at $254000.0 in Q2 2022.
Historically, Gross Profit has averaged $14.1 million across 5 years, with a median of $10.9 million in 2025.
Annual changes were most pronounced in 2022 — Gross Profit plunged 100.0% — and 2023, when it surged 9495.28%.
Glass House Brands' Gross Profit stood at $9.2 million in 2022, then jumped by 164.11% to $24.4 million in 2023, then climbed by 17.65% to $28.7 million in 2024, then plunged by 53.94% to $13.2 million in 2025, then fell by 24.16% to $10.0 million in 2026.
Business Quant data shows GLAS's Gross Profit at $10.0 million in Q1 2026, $13.2 million in Q4 2025, and $11.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-
10	Glass House Brands	825.81 Mn	807.26 Mn	15.77 Mn

Download Data